Soluble Tissue Factor in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 7, 2015, Pages 700-707

  Bogdanov, Vladimir Y ^a   Versteeg, Henri H ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alternative splicing; atherosclerosis; microparticle; thrombosis; tissue factor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; THROMBOPLASTIN; ISOPROTEIN;

ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; BLEEDING; BLOOD CLOTTING; DRUG TARGETING; HEMOSTASIS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOSIS; THROMBUS; VASCULAR TISSUE; VEIN THROMBOSIS; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; HUMANS; PROTEIN ISOFORMS; THROMBOPLASTIN; THROMBOSIS;

EID: 84943647105     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1556049     Document Type: Article

References (73)

1. Prager N. A., Abendschein D. R., McKenzie C. R., Eisenberg P. R. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation: 1995; 92 4 962 967
2. Toschi V., Gallo R., Lettino M., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation: 1997; 95 3 594 599
3. Marmur J. D., Thiruvikraman S. V., Fyfe B. S., et al. Identification of active tissue factor in human coronary atheroma. Circulation: 1996; 94 6 1226 1232
4. Key N. S., Slungaard A., Dandelet L., et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood: 1998; 91 11 4216 4223
5. Giesen P. L., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A: 1999; 96 5 2311 2315
6. Mallat Z., Hugel B., Ohan J., Lesèche G., Freyssinet J. M., Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation: 1999; 99 3 348 353
7. Schecter A. D., Spirn B., Rossikhina M., et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res: 2000; 87 2 126 132
8. Berckmans R. J., Nieuwland R., Böing A. N., Romijn F. P., Hack C. E., Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost: 2001; 85 4 639 646
9. Joop K., Berckmans R. J., Nieuwland R., et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost: 2001; 85 5 810 820
10. Diamant M., Nieuwland R., Pablo R. F., Sturk A., Smit J. W., Radder J. K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation: 2002; 106 19 2442 2447
11. Shet A. S., Aras O., Gupta K., et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood: 2003; 102 7 2678 2683
12. Bogdanov V. Y., Balasubramanian V., Hathcock J., Vele O., Lieb M., Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med: 2003; 9 4 458 462
13. Khan M. M., Hattori T., Niewiarowski S., Edmunds L. H. Jr, Colman R. W. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost: 2006; 95 3 462 468
14. Osterud B., Bjorklid E. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin. Scand J Haematol: 1982; 29 2 175 184
15. Muhlfelder T. W., Teodorescu V., Rand J., Rosman A., Niemetz J. Human atheromatous plaque extracts induce tissue factor activity (TFa) in monocytes and also express constitutive TFa. Thromb Haemost: 1999; 81 1 146 150
16. Chen V. M., Hogg P. J. Encryption and decryption of tissue factor. J Thromb Haemost: 2013; 11 Suppl 1 277 284
17. Fogelson A. L., Kuharsky A. L. Membrane binding-site density can modulate activation thresholds in enzyme systems. J Theor Biol: 1998; 193 1 1 18
18. Spicer E. K., Horton R., Bloem L., et al. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A: 1987; 84 15 5148 5152
19. Fiore M. M., Neuenschwander P. F., Morrissey J. H. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem: 1994; 269 1 143 149
20. Banner D. W., D'Arcy A., Chène C., et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature: 1996; 380 6569 41 46
21. Bogdanov V. Y., Kirk R. I., Miller C., et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost: 2006; 4 1 158 167
22. Bogdanov V. Y. Blood coagulation and alternative pre-mRNA splicing: an overview. Curr Mol Med: 2006; 6 8 859 869
23. Wang J. G., Geddings J. E., Aleman M. M., et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood: 2012; 119 23 5543 5552
24. van den Berg Y. W., Osanto S., Reitsma P. H., Versteeg H. H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood: 2012; 119 4 924 932
25. Jakubowski J. A., Zhou C., Jurcevic S., et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res: 2014; 133 2 190 195
26. Arraud N., Linares R., Tan S., et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost: 2014; 12 5 614 627
27. Zwaal R. F., Schroit A. J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood: 1997; 89 4 1121 1132
28. Ashcroft B. A., de Sonneville J., Yuana Y., et al. Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics. Biomed Microdevices: 2012; 14 4 641 649
29. Davila M., Robles-Carrillo L., Unruh D., et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J Thromb Haemost: 2014; 12 2 186 196
30. Silberberg J. M., Gordon S., Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res: 1989; 49 19 5443 5447
31. Ettelaie C., Collier M. E., Maraveyas A., Ettelaie R. Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. J Extracell Vesicles: 2014;; doi: 10.3402/jev.v3.23592
32. Leiderman K., Fogelson A. An overview of mathematical modeling of thrombus formation under flow. Thromb Res: 2014; 133 Suppl 1 S12 S14
33. Szotowski B., Antoniak S., Poller W., Schultheiss H. P., Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res: 2005; 96 12 1233 1239
34. Biró E., Sturk-Maquelin K. N., Vogel G. M., et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost: 2003; 1 12 2561 2568
35. Owens A. P. III, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost: 2010; 104 3 432 439
36. Willemze R., Bradford R. L., Mooberry M. J., Roubey R. A., Key N. S. Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res: 2014; 133 2 187 189
37. Thaler J., Koppensteiner R., Pabinger I., Ay C., Gremmel T. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res: 2014; 134 5 1093 1096
38. Walenga J. M., Kaiser P. C., Prechel M. M., et al. Sustained release of tissue factor following thrombosis of lower limb trauma. Clin Appl Thromb Hemost: 2014; 20 7 678 686
39. Ye R., Ye C., Huang Y., Liu L., Wang S. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res: 2012; 130 2 253 258
40. Kooiman J., den Exter P. L., Kilicsoy I., et al. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. J Thromb Thrombolysis: 2015; 40 3 323 330
41. Khorana A. A., Ahrendt S. A., Ryan C. K., et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res: 2007; 13 10 2870 2875
42. Thaler J., Koder S., Kornek G., Pabinger I., Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res: 2014; 163 2 145 150
43. Johansson H., Lukinius A., Moberg L., et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes: 2005; 54 6 1755 1762
44. Haas S. L., Jesnowski R., Steiner M., et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol: 2006; 12 30 4843 4849
45. Hobbs J. E., Zakarija A., Cundiff D. L., et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res: 2007; 120 (Suppl 2) S13 S21
46. van den Berg Y. W., van den Hengel L. G., Myers H. R., et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A: 2009; 106 46 19497 19502
47. Unruh D., Turner K., Srinivasan R., et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer: 2014; 134 1 9 20
48. Unruh D., Sagin F., Adam M., et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype (e-pub ahead of print). Ann Surg Oncol PMID: 25963480
49. Lind C., Flinterman L. E., Enga K. F., et al. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation: 2014; 129 8 855 863
50. Rauch U., Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med: 2000; 10 4 139 143
51. Himber J., Kling D., Fallon J. T., Nemerson Y., Riederer M. A. In situ localization of tissue factor in human thrombi. Blood: 2002; 99 11 4249 4250
52. Balasubramanian V., Grabowski E., Bini A., Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood: 2002; 100 8 2787 2792
53. Camera M., Brambilla M., Facchinetti L., et al. Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb Res: 2012; 129 3 279 284
54. Rauch U., Bonderman D., Bohrmann B., et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood: 2000; 96 1 170 175
55. Del Conde I., Shrimpton C. N., Thiagarajan P., López J. A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood: 2005; 106 5 1604 1611
56. Palmerini T., Tomasi L., Barozzi C., et al. Detection of tissue factor antigen and coagulation activity in coronary artery thrombi isolated from patients with ST-segment elevation acute myocardial infarction. PLoS ONE: 2013; 8 12 e81501
57. Karnicki K., Owen W. G., Miller R. S., McBane R. D. II. Factors contributing to individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol: 2002; 22 9 1495 1499
58. Clowes A. W., Clowes M. M., Fingerle J., Reidy M. A. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol: 1989; 14 Suppl 6 S12 S15
59. Srinivasan R., Ozhegov E., van den Berg Y. W., et al. Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling. J Thromb Haemost: 2011; 9 10 2087 2096
60. Kocatürk B., Versteeg H. H. Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill. J Thromb Haemost: 2013; 11 01 285 293
61. Giannarelli C., Alique M., Rodriguez D. T., et al. Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling. Circulation: 2014; 130 15 1274 1286
62. Kocatürk B., Van den Berg Y. W., Tieken C., et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A: 2013; 110 28 11517 11522
63. Eisenreich A., Zakrzewicz A., Huber K., et al. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol Rep: 2013; 30 1 462 470
64. Wang J., Wang H., Guo C., et al. Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice. PLoS ONE: 2014; 9 2 e90146
65. Godby R. C., Van Den Berg Y. W., Srinivasan R., et al. Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models. Mol Med: 2012; 18 771 779
66. Borissoff J. I., Heeneman S., Kilinç E., et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation: 2010; 122 8 821 830
67. Unruh D., Qi X., Chu Z., et al. Antibody-based targeting of alternatively spliced tissue factor impedes the growth and aggressiveness of pancreatic ductal adenocarcinoma. J Thromb Haemost: 2015; 13 02 111
68. Gruber A. The role of the contact pathway in thrombus propagation. Thromb Res: 2014; 133 Suppl 1 S45 S47
69. Puy C., Tucker E. I., Matafonov A., et al. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood: 2015; 125 9 1488 1496
70. Stavrou E. X., Fang C., Merkulova A., et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood: 2015; 125 4 710 719
71. Fareed J. Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy. Nat Rev Cardiol: 2015; 12 2 70 71
72. Chandradas S., Deikus G., Tardos J. G., Bogdanov V. Y. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. J Leukoc Biol: 2010; 87 1 147 152
73. Eisenreich A., Bogdanov V. Y., Zakrzewicz A., et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res: 2009; 104 5 589 599